TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16051399
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri ATCC 55730, 1x10(8) cfu/tablet twice a day for 6 months
Study: 11824856
Drug: L-arginine 100
Normalized name: RITE AID L-Arginine 1000mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 100 mg/kg
Study: 11824856
Drug: L-arginine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 250 mg/kg
Study: 11824856
Drug: L-arginine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 250 mg/kg with L-NMMA
Study: 11824856
Drug: L-NMMA before
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA before L-arginine infusion
Study: 11824856
Drug: Subsequent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subsequent infusion of L-arginine after L-NMMA
Study: 10073501
Drug: Hyaluronan loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan loading test with intravenous injection of 7.5 mg HYA
Study: 7722709
Drug: High protein-energy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein-energy supplement (Atole)
Study: 7722709
Drug: Low-energy, no-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy, no-protein supplement (Fresco)
Study: 2183665
Drug: Ibuprofen, 800
Normalized name: Ibuprofen, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 800 mg three times daily
Study: 2183665
Drug: Piroxicam, 20
Normalized name: Piroxicam, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam, 20 mg daily
Study: 2183665
Drug: Sulindac, 200
Normalized name: Sulindac, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac, 200 mg twice daily
Study: 2183665
Drug: Ibuprofen, piroxicam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, piroxicam, and sulindac (combined)
Study: 6276883
Drug: Calcium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium therapy (Control group, n = 9)
Study: 31923471
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (INI) 40 IU daily for 24 weeks
Study: 30799103
Drug: Twice-a-day milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day milk feeding with live yeast culture and mannan-rich fraction
Study: 30799103
Drug: Twice-a-day milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day milk feeding without yeast
Study: 30799103
Drug: Calves fed
Normalized name: AmproMed for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calves fed milk twice a day
Study: 30799103
Drug: Calves fed
Normalized name: AmproMed for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calves fed milk once or twice a day
Study: 19458560
Drug: Microdose transdermal
Normalized name: LANCET,MICRODOT SAFETY 28G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose transdermal E2 (0.014 mg/d)
Study: 19458560
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal E2 plus levonorgestrel (0.023 mg/d E2/0.0075 mg/d levonorgestrel)
Study: 17766600
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter with extraamniotic saline infusion
Study: 15099990
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) (25 mg sulfadoxine and 1.25 mg pyrimethamine/kg)
Study: 15099990
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) (25 mg/kg)
Study: 8018453
Drug: Anpirtoline (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anpirtoline (60 mg orally)
Study: 8018453
Drug: Tramadol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (150 mg orally)
Study: 1103074
Drug: Dyphylline 15
Normalized name: dyphylline 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyphylline 15 mg/kg
Study: 31602966
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg extended-release oral trospium 1 h before induction of anesthesia
Study: 31200321
Drug: pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 200 mg every 3 weeks for a total of 18 doses (∼1 year)
Study: 31200321
Drug: placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo every 3 weeks for a total of 18 doses (∼1 year)
Study: 22840286
Drug: Olanzapine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (4 weeks treatment)
Study: 22840286
Drug: Pre-treatment (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment (no medication)
Study: 19321562
Drug: SE and
Normalized name: Cleanse and Treat
Approvals — FDA: no, EMA: no, PMDA: no
Description: SE and SS treatments
Study: 11592726
Drug: CLA supplementation
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLA supplementation (3.9 g/d for 64 d)
Study: 7988302
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment given by community health centers
Study: 29855271
Drug: Maternal nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal nutritional supplement (140 kcal/serving, 7.9 g protein, multivitamin/minerals, with or without probiotics)
Study: 27765800
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (400 μg/d for 12 weeks)
Study: 8751017
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release (CR) diltiazem, given twice a day (b.i.d.)
Study: 30857647
Drug: Veverimer 6
Normalized name: Veverimer
DrugBank: Veverimer (DB18977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veverimer 6 g/day
Study: 27661788
Drug: Patient-centered methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered methadone treatment (PCM; n = 149)
Study: 27661788
Drug: Treatment-as-usual (TAU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU; n = 151)
Study: 25385260
Drug: Decernotinib 25
Normalized name: Decernotinib
DrugBank: Decernotinib (DB12566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decernotinib 25 mg
Study: 25385260
Drug: Decernotinib 50
Normalized name: Decernotinib
DrugBank: Decernotinib (DB12566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decernotinib 50 mg
Study: 25385260
Drug: Decernotinib 100
Normalized name: Decernotinib
DrugBank: Decernotinib (DB12566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decernotinib 100 mg
Study: 25385260
Drug: Decernotinib 150
Normalized name: Decernotinib
DrugBank: Decernotinib (DB12566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decernotinib 150 mg
Study: 21854643
Drug: Structured medication
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured medication assessment including withdrawal of fall-risk increasing drugs
Study: 9621140
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily for 3 months followed by itraconazole 200 mg once weekly for 3 months (ITR-ITR group)
Study: 9621140
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily for 3 months followed by oral placebo once weekly for 3 months (ITR-PLAC group)
Study: 9621140
Drug: Miconazole cream
Normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole cream twice daily for 6 months (MIC-MIC group)
Study: 8173149
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg q12h
Study: 8173149
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 units q8h
Study: 8173149
Drug: Enoxaparin groups
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin groups (30 mg and 40 mg)
Study: 27431049
Drug: Buprenorphine linkage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine linkage (induction, stabilization, bridge prescription, and facilitated referral to outpatient treatment)
Study: 27431049
Drug: Detoxification (5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detoxification (5-day inpatient buprenorphine taper)
Study: 24933451
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (ICBT), 7-10 weekly modules guided by online therapists
Study: 22870676
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection with sodium hyaluronate (Control)
Study: 19465145
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) plus behavior therapy
Study: 19465145
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy only (Control)
Study: 15223858
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose (DD) of inhaled corticosteroid
Study: 15223858
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose (MD) of inhaled corticosteroid
Study: 8279255
Drug: 2-hour fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Study: 8279255
Drug: 4-hour fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Study: 8279255
Drug: 12-hour fasting
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Study: 31648815
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 3 g per day for 5 days before and 21 days after surgery
Study: 29114733
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (3.0 to 9.0 g per night for 6 weeks)
Study: 15774213
Drug: Gabapentin 200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 200 mg/d
Study: 12695266
Drug: Low-molecular-weight heparin(s)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin(s)
Study: 12695266
Drug: Ximelagatran (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (direct thrombin inhibitor)
Study: 12695266
Drug: Nematode anticoagulant
Normalized name: Recombinant nematode anticoagulant protein-2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nematode anticoagulant peptide c2 (tissue factor VIIa inhibitor)
Study: 12695266
Drug: Sodium N-[8(2-hydroxylbenzoyl)amino]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium N-[8(2-hydroxylbenzoyl)amino] caprylate (SNAC)/heparin (heparin derivative)
Study: 12695266
Drug: Fondaparinux (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (selective factor Xa inhibitor)
Study: 10323374
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DHEA for 3 months
Study: 8630575
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg zileuton, a 5-lipoxygenase inhibitor
Study: 2006743
Drug: 240 mL
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mL water
Study: 2006743
Drug: 240 mL
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mL coffee
Study: 2006743
Drug: 240 mL
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mL pulp-free orange juice
Study: 28961737
Drug: Miltefosine combination
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine combination therapy
Study: 17410417
Drug: Oral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral opioid blockade
Study: 15704589
Drug: Xuesaitong Injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong Injection, i.v., once a day for 14 days
Study: 15704589
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy with western medicine (Control)
Study: 15704589
Drug: Xuesaitong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong Injection
Study: 9257765
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg administered at 1000 hours
Study: 9257765
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg administered at 2200 hours
Study: 7693424
Drug: Tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 30 mg/day orally for 3 years (Group A, n = 192)
Study: 7693424
Drug: Tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 30 mg/day orally for 3 years plus FEC 50 for 6 cycles (Group C, n = 182)
Study: 7693424
Drug: No medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medical adjuvant treatment (Group D, n = 184)
Study: 3121334
Drug: rt-PA +
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA + heparin
Study: 3121334
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + heparin
Study: 28636851
Drug: Chemotherapy (platinum-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (platinum-based, administered once every 3 weeks for up to six cycles)
Study: 20374312
Drug: CLAs 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLAs 2.5 g
Study: 53370
Drug: Group-A polysaccharide
Normalized name: meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-A polysaccharide vaccine
Study: 27761791
Drug: Probiotics (L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (L. acidophilus, L. rhamnosus, and L. sporogenes)
Study: 25879008
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg (group A)
Study: 25879008
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg/kg (group B)
Study: 25879008
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg (group A) and Sugammadex 4 mg/kg (group B)
Study: 23444169
Drug: Diflunisal-Naproxen fixed-dose
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal-Naproxen fixed-dose combination (FDC) tablet
Study: 23444169
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of two separate diflunisal and naproxen marketed tablets
Study: 21120461
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin 1000 mg/day for 2 days, followed by 2000 mg/day for 5 days
Study: 21120461
Drug: Ezetimibe/simvastatin 10
Normalized name: Ezetimibe/Simvastatin 10 MG-10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10 mg/20 mg/day
Study: 21120461
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of extended-release niacin and ezetimibe/simvastatin
Study: 20110026
Drug: Barnidipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine (10-20 mg once daily)
Study: 17275927
Drug: Unilateral cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral cochlear implant turned on
Study: 17275927
Drug: Unilateral cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral cochlear implant turned off
Study: 15533270
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of substitution and reduction strategies
Study: 11322357
Drug: Thyroxine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine therapy for subclinical hypothyroidism with TSH > 10 mIU/L
Study: 11322357
Drug: Individualized decision
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized decision for therapy for subclinical hypothyroidism with TSH between 5 and 10 mIU/L
Study: 11322357
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for subclinical hyperthyroidism
Study: 9491823
Drug: CP-105,696 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-105,696 (5 to 640 mg single oral dose)
Study: 7819683
Drug: Graseby capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graseby capsule
Study: 2512163
Drug: Antibiotics (mainly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (mainly ampicillin and netilmicin)
Study: 1180124
Drug: Phenobarbital 100
Normalized name: phenobarbital 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 100 mg daily for 7 days
Study: 1180124
Drug: Diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15 mg daily for 7 days
Study: 1180124
Drug: Oxazepam 75
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam 75 mg daily for 7 days
Study: 29515726
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hypobaric bupivacaine
Study: 29515726
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hypobaric bupivacaine
Study: 16143706
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus warfarin (A+W)
Study: 16143706
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus warfarin (A+W) with INR of 2-3
Study: 15058044
Drug: Incremental cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental cycling exercise test after blood donation (450 ml)
Study: 8686260
Drug: French measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: French measles vaccine
Study: 8686260
Drug: Japanese measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese measles vaccine
Study: 8686260
Drug: Russian measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Russian measles vaccine
Study: 31060605
Drug: Anti-malarial treatment
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-malarial treatment of patients with negative malaria test in Maputo Province (8%, 2-23)
Study: 31060605
Drug: Anti-malarial treatment
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-malarial treatment of patients with negative malaria test in Zambézia (22%, 14-32)
Study: 31060605
Drug: Correct recitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correct recitation of dosing instructions for anti-malarial treatment (58-62%)
Study: 28264130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (identical medical agents postoperatively)
Study: 26621819
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg plus omeprazole 40 mg
Study: 30557377
Drug: Neuromuscular blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blockade (NMB) infusion for 24 hours
Study: 30557377
Drug: NMB infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NMB infusion
Study: 27803393
Drug: Carotid narrowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid narrowing over 50% and hsCRP levels >0.29 mg/dL
Study: 24671507
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg oral daily plus bicalutamide 50 mg oral daily (Arm A)
Study: 24671507
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg oral daily alone (Arm B)
Study: 20855048
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Therapy for Adolescents (PE‐A)
Study: 20855048
Drug: Time-Limited Dynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-Limited Dynamic Therapy for Adolescents (TLDP‐A)
Study: 17661955
Drug: Desipramine 100
Normalized name: desipramine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 100 mg/d
Study: 17661955
Drug: Gabapentin 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,800 mg/d
Study: 9071556
Drug: 0.05% desonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% desonide ointment
Study: 2082488
Drug: Aspirin-dipyridamole combination
Normalized name: aspirin / dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-dipyridamole combination
Study: 582746
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 1 mg difenoxin hydrochloride (Lyspafen)
Study: 23927461
Drug: Single hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single hydroxyurea (HU) therapy
Study: 11320043
Drug: rhG‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG‐CSF (10 microg/kg/day) administered intravenously
Study: 8396091
Drug: Single oral-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral-dose of 1 g azithromycin